nach oben

Drugs

Erschienen in:

01.02.2006 | Review Article

Mitomycin

Clinical Applications in Ophthalmic Practice

verfasst von: Lekha M. Abraham, Dinesh Selva, Robert Casson, Dr Igal Leibovitch

Erschienen in: Drugs | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Mitomycin (mitomycin C; MMC) is an antibiotic isolated from Streptomyces caespitosus. The drug is a bioreductive alkylating agent that undergoes metabolic reductive activation, and has various oxygen tension-dependent cytotoxic effects on cells, including the cross-linking of DNA. It is widely used systemically for the treatment of malignancies, and has gained popularity as topical adjunctive therapy in ocular and adnexal surgery over the past 2 decades.

In ophthalmic medicine, it is principally used to inhibit the wound healing response and reduce scarring of surgically fashioned ostia. Hence, it has been used as adjunctive therapy in various ocular surgeries, such as glaucoma filtering surgeries, dacryocystorhinostomy, corneal refractive surgery and surgeries for ocular cicatrisation. In addition, it has been used as an adjunct in the surgical management of pterygia, ocular surface squamous neoplasia, primary acquired melanosis with atypia and conjunctival melanoma. In many of these surgeries and ophthalmic pathologies, MMC showed a significant beneficial effect.

Verweij J, Pinedo HM. Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1990; 1(1): 5–13PubMedCrossRef

Reddy MV, Randerath K. 32P-analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic, mitomycin C. Mutat Res 1987; 179(1): 75–88PubMedCrossRef

Lown JW. The molecular mechanism of action of the mitomycins. In: Carter SK, Crooke ST, eds. Mitomycin: current status and new developments. New York: Academic Press, 1979: 243–51

Jampel HD. Effect of brief exposure of mitomycin C on viability and proliferation of cultured human Tenon’s capsule fibroblasts. Ophthalmology 1992; 99: 1471–6PubMed

Crowston JG, Akbar AN, Constable PH, et al. Antimetabolite-induced apoptosis in Tenon’s capsule fibroblasts. Invest Ophthalmol Vis Sci 1998; 39(2): 449–54PubMed

Francis BA, Du LT, Najafi K, et al. Histopathologic features of conjunctival filtering blebs. Arch Ophthalmol 2005; 123(2): 166–70PubMedCrossRef

Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003; 48: 314–46PubMedCrossRef

Kawase K, Matsushita H, Yamamoto T, et al. Mitomycin concentration in rabbit and human ocular tissues after topical administration. Ophthalmology 1992; 99(2): 203–7PubMed

Seah SK, Prata JA, Minckler DS. Mitomycin C concentration in the human ocular tissues following trabeculectomy. Eye 1993; 7: 652–5PubMedCrossRef

10.

Costa PV, Spaeth GL, Eiferman RA, et al. Wound healing modulation in glaucoma filtering surgery. Ophthalmic Surg 1993; 24(3): 152–70PubMed

11.

Peng TK, Migdal CS. Current techniques in wound healing modulation in glaucoma surgery. Curr Opin Ophthalmol 1996; 7(2): 24–33CrossRef

12.

Leske MC, Anders H, Hussein M, et al. Factors for glaucoma prevention and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121(1): 48–57PubMedCrossRef

13.

Chen CW, Huang HT, Bair JS, et al. Trabeculectomy with simultaneous topical application of mitomycin C in refractory glaucoma. J Ocul Pharmacol 1990; 6: 175–82PubMedCrossRef

14.

Kitazawa Y, Suemori-Matsushita H, Yamamoto T, et al. Low-dose and high-dose mitomycin trabeculectomy as an initial surgery in primary open-angle glaucoma (0.02 vs 0.002). Ophthalmology 1993; 100(11): 1624–8PubMed

15.

Spaeth GL, Mutlukan E. The use of antimetabolites with trabeculectomy: a critical appraisal. J Glaucoma 2001; 10(3): 145–51PubMedCrossRef

16.

Joshi AB, Parrish RK, Feuer WF. 2002 survey of the American Glaucoma Society: practice preferences for glaucoma surgery and antifibrotic use. J Glaucoma 2005; 14: 172–4PubMedCrossRef

17.

Neelakantan A, Rao BS, Vijaya L, et al. Effect of the concentration and duration of application of mitomycin C in trabeculectomy. Ophthalmic Surg 1994; 25(9): 612–5PubMed

18.

Stone RT, Herndon LW, Allingham RR, et al. Results of trabeculectomy with 0.3 mg/ml mitomycin C titrating exposure times based on risk factors for failure. J Glaucoma 1998; 7(1): 39–44PubMedCrossRef

19.

Bindlish R, Condon GP, Schlosser JD, et al. Efficacy and safety of mitomycin-C in primary trabeculectomy: five-year follow-up. Ophthalmology 2002; 109(7): 1336–41PubMedCrossRef

20.

Casson R, Rahman R, Salmon JF. Long term results and complications of trabeculectomy augmented with low dose mitomycin C in patients at risk for filtration failure. Br J Ophthalmol 2001; 85(6): 686–8PubMedCrossRef

21.

Cheung JC, Wright MM, Murali S, et al. Intermediate-term outcome of variable dose mitomycin C filtering surgery. Ophthalmology 1997; 104(1): 143–9PubMed

22.

Perkins TW, Gangnon R, Ladd W, et al. Trabeculectomy with mitomycin C: intermediate-term results. J Glaucoma 1998; 7(4): 230–6PubMedCrossRef

23.

Akarsu C, Onol M, Hasanreisoglu B. Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up. Clin Exp Ophthalmol 2003; 31(3): 199–205CrossRef

24.

Beckers HJ, Kinders KC, Webers CA. Five-year results of trabeculectomy with mitomycin C. Graefes Arch Clin Exp Ophthalmol 2003; 241(2): 106–10PubMedCrossRef

25.

Nuijts RM, Vernimmen RC, Webers CA. Mitomycin C primary trabeculectomy in primary glaucoma of white patients. J Glaucoma 1997; 6: 293–7PubMedCrossRef

26.

Lamping KA, Belkin JK. 5-Flourouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995; 102: 70–5PubMed

27.

Casson R, Salmon JF. Combined surgery in the treatment of patients with cataract and primary open angle glaucoma. J Cataract Refract Surg 2001; 27: 1854–63PubMedCrossRef

28.

Carlson DW, Alward WL, Barad JP, et al. A randomized study of mitomycin augmentation in combined phacoemulsification and trabeculectomy. Ophthalmology 1997; 104: 719–24PubMed

29.

Cohen JS, Greff LJ, Novack GD, et al. A placebo controlled double masked evaluation of mitomycin C in combined glaucoma and cataract procedures. Ophthalmology 1996; 103: 1934–42PubMed

30.

Shin DH, Ren J, Juzych MS, et al. Primary glaucoma triple procedure in patients with primary open angle glaucoma: the effect of mitomycin C in patients with and without prognostic factors for filtration failure. Am J Ophthalmol 1998; 125: 346–52PubMedCrossRef

31.

Shin DH, Iskander NG, Ahee JA, et al. Long-term filtration and visual field outcomes after primary glaucoma triple procedure with and without mitomycin-C. Ophthalmology 2002; 109(9): 1607–11PubMedCrossRef

32.

Wilkins M, Indar A, Wormald R. Intraoperative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev 2001; (1): CD002897

33.

Kleinmann G, Katz H, Pollack A, et al. Comparison of trabeculectomy with mitomycin C with or without phaco emulsification and intraocular lens implantation. Ophthalmic Surg Lasers 2002; 33: 102–8PubMed

34.

Vass C, Menapace R. Surgical Strategies in patients with combined cataract and glaucoma. Curr Opin Ophthalmol 2004; 15: 61–6PubMedCrossRef

35.

Siriwardena D, Kotecha A, Minassian D, et al. Anterior chamber flare after trabeculectomy and after phacoemulsification. Br J Ophthalmol 2000; 84(9): 1056–7PubMedCrossRef

36.

Lochhead J, Casson RJ, Salmon JF. Long term effect on intraocular pressure of phacotrabeculectomy compared to trabeculectomy. Br J Ophthalmol 2003; 87: 850–2PubMedCrossRef

37.

Kosmin AS, Wishart PK, Ridges PJ. Long-term intraocular pressure control after cataract extraction with trabeculectomy: phacoemulsification versus extracapsular technique. J Cataract Refract Surg 1998; 24(2): 249–55PubMed

38.

Tezel G, Kolker AE, Kass MA, et al. Comparative results of combined procedures for glaucoma and cataract: I. Extracapsular cataract extraction versus phacoemulsification and foldable versus rigid intraocular lenses. Ophthalmic Surg Lasers 1997; 28(7): 539–50

39.

al-Hazmi A, Zwaan J, Awad A, et al. Effectiveness and complications of mitomycin C use during pediatric glaucoma surgery. Ophthalmology 1998; 105(10): 1915–20PubMedCrossRef

40.

Mullaney PB, Selleck C, Al-Awad A, et al. Combined trabeculotomy and trabeculectomy as an initial procedure in uncomplicated congenital glaucoma. Arch Ophthalmol 1999; 117(4): 457–60PubMedCrossRef

41.

Mandal AK, Prasad K, Naduvilath TJ. Surgical results and complications of mitomycin C augmented trabeculectomy in refractory developmental glaucoma. Ophthal Surg Lasers 1999; 30: 473–80

42.

Rodrigues AM, Junior AP, Montezano FT, et al. Comparison between results of trabeculectomy in primary congenital glaucoma with and without the use of mitomycin C. J Glaucoma 2004; 13(3): 228–32PubMedCrossRef

43.

Al-Hazmi A, Awad A, Zwaan J, et al. Correlation between surgical success rate and severity of congenital glaucoma. Br J Ophthalmol 2005; 89(4): 449–53PubMedCrossRef

44.

Mandal AK, Walton DS, John T, et al. Mitomycin C-augmented trabeculectomy in refractory congenital glaucoma. Ophthalmology 1997; 104(6): 996–1001PubMed

45.

Cantor L, Burgoyne J, Sanders S, et al. The effect of mitomycin C on Molteno implant surgery. J Glaucoma 1998; 7: 240–6PubMedCrossRef

46.

Perkins TW, Gangnon R, Ladd W, et al. Molteno implant with mitomycin C: intermediate term results. J Glaucoma 1998; 7: 86–92PubMed

47.

Azuara-Blanco A, Moster MR, Wilson RP, et al. Simultaneous use of mitomycin C with Baerveldt implantation. Ophthalmic Surg Lasers 1997; 28: 992–7PubMed

48.

Lee D, Flores RA, Anderson PJ, et al. The effect of adjunctive mitomycin C in Molteno implant surgery. Ophthalmology 1997; 104: 2126–35PubMed

49.

Costa VP, Azuora-Blanca A, Netland PA, et al. Efficacy and safety of adjunctive mitomycin C during Ahmed glaucoma valve implantation: a prospective randomized clinical trial. Ophthalmology 2004; 111(6): 1071–6PubMedCrossRef

50.

Mardelli PG, Lederer CM, Murray PL, et al. Slit-lamp needle revision of failed filtering blebs using mitomycin C. Ophthalmology 1996; 103(11): 1946–55PubMed

51.

Iwach AG, Delgado MF, Novack GD, et al. Transconjunctival mitomycin-C in needle revisions of failing filtering blebs. Ophthalmology 2003; 110(4): 734–42PubMedCrossRef

52.

Shetty RK, Wartluft L, Moster MR. Slit-lamp needle revision of failed filtering blebs using high-dose mitomycin C. J Glaucoma 2005; 14(1): 52–6PubMedCrossRef

53.

Jaros PA, De Luise VP. Pingueculae and pterygia. Surv Ophthalmol 1988; 33: 41–9PubMedCrossRef

54.

Saw SM, Banerjee K, Tan D. Risk factors for the development of pterygium in Singapore: a hospital-based case-control study. Acta Ophthalmol Scand 2000; 78: 216–20PubMedCrossRef

55.

Saw SM, Tan D. Pterygium: prevalence, demography and risk factors. Ophthalmic Epidemiol 1999; 6: 219–28PubMedCrossRef

56.

McCarty CA, Fu CL, Taylor HR. Epidemiology of pterygium in Victoria, Australia. Br J Ophthalmol 2000; 84: 289–92PubMedCrossRef

57.

Kwok LS, Coroneo MT. A model for pterygium formation. Cornea 1994; 13(3): 219–24PubMedCrossRef

58.

Dion E. The treatment of pterygium. Ophthalmic Surg 1977; 8: 12–30

59.

Kenyon KR, Wagoner MD, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology 1985; 92: 1461–70PubMed

60.

Shaw EL. A modified technique for conjunctival transplant. CLAO J 1992; 18: 112–6PubMed

61.

Lewallen S. A randomized controlled trial of conjunctival autografting for pterygium in the tropics. Ophthalmology 1989; 96: 1612–4PubMed

62.

Chen PP, Ariyasu RG, Kaza V, et al. A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol 1995; 120: 151–60PubMed

63.

Ma DH, See LC, Hwang YS, et al. Comparison of amniotic membrane graft alone or combined with intraoperative mitomycin C to prevent recurrence after excision of recurrent pterygia. Cornea 2005; 24(2): 141–50PubMedCrossRef

64.

Essex RW, Snibson GR, Daniell M, et al. Amniotic membrane grafting in the surgical management of primary pterygium. Clin Exp Ophthalmol 2004; 32(5): 501–4CrossRef

65.

Basti S, Rao SK. Current status of limbal conjunctival autograft. Curr Opin Ophthalmol 2000; 11(4): 224–32PubMedCrossRef

66.

Hayasaka S, Noda S, Yamamoto Y, et al. Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol 1988; 106(6): 715–8PubMed

67.

Singh G, Wilson MR, Foster CS. Mitomycin eye drops as treatment for pterygium. Ophthalmology 1988; 95: 813–21PubMed

68.

Fujitani A, Hayasaka S, Shibuya Y, et al. Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy. Ophthalmologica 1993; 207(3): 162–4PubMedCrossRef

69.

Rubinfeld RS, Pfister RR, Stein RM, et al. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology 1992; 99(11): 1647–54PubMed

70.

Frucht-Pery J, Ilsar M. The use of low-dose mitomycin C for prevention of recurrent pterygium. Ophthalmology 1994; 101(4): 759–62PubMed

71.

Frucht-Pery J, Ilsar M, Hemo I. Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report. Cornea 1994; 13(5): 411–3PubMedCrossRef

72.

Frucht-Pery J, Siganos CS, Ilsar M. Intraoperative application of topical mitomycin C for pterygium surgery. Ophthalmology 1996; 103(4): 674–7PubMed

73.

Caliskan S, Orhan M, Irkec M. Intraoperative and postoperative use of mitomycin-C in the treatment of primary pterygium. Ophthalmic Surg Lasers 1996; 27(7): 600–4PubMed

74.

Cardillo JA, Alves MR, Ambrosio LE, et al. Single intraoperative application versus post operative mitomycin C eye drops in pterygium surgery. Ophthalmology 1995; 102: 1949–52PubMed

75.

Manning CA, Kloess PM, Diaz MD, et al. Intraoperative mitomycin in primary pterygium excision: a prospective randomized trial. Ophthalmology 1997; 108: 844–8

76.

Lam DS, Wong AK, Fan DS, et al. Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30 month follow up study. Ophthalmology 1998; 105: 901–4PubMedCrossRef

77.

Cheng HC, Tseng SH, Kao PL, et al. Low-dose intraoperative mitomycin C as chemoadjuvant for pterygium surgery. Cornea 2001; 20(1): 24–9PubMedCrossRef

78.

Donnenfeld ED, Perry HD, Fromer S, et al. Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. Ophthalmology 2003; 110: 1012–26PubMedCrossRef

79.

Raiskup F, Solomon A, Landau D, et al. Mitomycin C for pterygium: long term evaluation. Br J Ophthalmol 2004; 88: 1425–8PubMedCrossRef

80.

Murakami M, Mori S, Kunitomo N. Studies on the pterygium: V. Follow-up information of mitomycin C treatment. Nippon Ganka Gakkai Zasshi 1967; 71(4): 351–8

81.

Young AL, Leung GYS, Wong AKK, et al. A randomized trial comparing 0.02% mitomycin C and limbal conjunctival autograft after excision of primary pterygium. Br J Ophthalmol 2004; 88: 995–7PubMedCrossRef

82.

Segev F, Jaeger-Roshu S, Gefen-Carmi N, et al. Combined mitomycin C application and free flap conjunctival autograft in pterygium surgery. Cornea 2003; 22: 598–603PubMedCrossRef

83.

Toti A. Nuovo metodo conservatore di cura radicale delle suporazioni chroniche del sacco lacrimale. Clin Mod Firenze 1904; 10: 385–9

84.

Dupuy-Dutemps L, Bourguet J. Procède plastique de dacryocystorhinostomie et ses resultats. Ann Ocul (Paris) 1921; 158: 241–61

85.

Iliff CE. A simplified dacryocystorhinostomy. Arch Ophthalmol 1971; 85: 586–91PubMedCrossRef

86.

Pico G. A modified technique of external dacryocystorhinostomy. Am J Ophthalmol 1971; 72: 679–89PubMed

87.

Tarbet KJ, Custer PL. External dacryocystorhinostomy: surgical success, patient satisfaction, and economic cost. Ophthalmology 1995; 102: 1065–70PubMed

88.

Welham RAN, Wulc AE. Management of unsuccessful lacrimal surgery. Br J Ophthalmol 1987; 71: 152–7PubMedCrossRef

89.

Walland MJ, Rose GE. Factors affecting the success rate of open lacrimal surgery. Br J Ophthalmol 1994; 78: 888–91PubMedCrossRef

90.

Liao SL, Kao SC, Tseng JH, et al. Results of intraoperative mitomycin C application in dacryocystorhinostomy. Br J Ophthalmol 2000; 84(8): 903–6PubMedCrossRef

91.

Linberg JV, Anderson RL, Bumsted RM, et al. Study of intranasal ostium external dacryocystorhinostomy. Arch Ophthalmol 1982; 100: 1758–62PubMedCrossRef

92.

Kao SC, Liao CL, Tseng JH, et al. Dacryocystorhinostomy with intraoperative mitomycin C. Ophthalmology 1997; 104(1): 86–91PubMed

93.

You YA, Fang CT. Intraoperative mitomycin C in dacryocystorhinostomy. Ophthal Plast Reconstr Surg 2001; 17(2): 115–9PubMedCrossRef

94.

Roozitalab MH, Amirahmadi M, Namazi MR. Results of the application of intraoperative mitomycin C in dacryocystorhinostomy. Eur J Ophthalmol 2004; 14(6): 461–3PubMed

95.

Yeatts RP, Neves RB. Use of mitomycin C in repeat dacryocystorhinostomy. Ophthal Plast Reconstr Surg 1999; 15(1): 19–22PubMedCrossRef

96.

Zilelioglu G, Ugurbas SH, Anadolu Y, et al. Adjunctive use of mitomycin C on endoscopic lacrimal surgery. Br J Ophthalmol 1998; 82(1): 63–6PubMedCrossRef

97.

Camara JG, Bengzon AU, Henson RD. The safety and efficacy of mitomycin C in endonasal endoscopic laser-assisted dacryocystorhinostomy. Ophthal Plast Reconstr Surg 2000; 16(2): 114–8PubMedCrossRef

98.

Kaufman LM, Guay-Bhatia LA. Monocanalicular intubation with Monoka tubes for the treatment of congenital nasolacrimal duct obstruction. Ophthalmology 1998; 105(2): 336–41PubMedCrossRef

99.

Fulcher T, O’Connor M, Moriarty P. Nasolacrimal intubation in adults. Br J Ophthalmol 1998; 82(9): 1039–41PubMedCrossRef

100.

Liu D, Bosley TM. Silicone nasolacrimal intubation with mitomycin C: a prospective randomized, double masked study. Ophthalmology 2003; 110: 306–10PubMedCrossRef

101.

Lam S, Tessler HH. Mitomycin as adjunct therapy in correcting iatrogenic punctal stenosis. Ophthalmic Surg 1993; 24(2): 123–4PubMed

102.

Ma’luf RN, Hamush NG, Awwad ST, et al. Mitomycin C as adjunct therapy in correcting punctal stenosis. Ophthal Plast Reconstr Surg 2002; 18(4): 285–8PubMedCrossRef

103.

Gartry DS, Kerr Muir MG, Marshall J. Excimer laser photorefractive keratectomy: 18 month follow up. Ophthalmology 1992; 99: 1209–19PubMed

104.

Lee YC, Hu FR, Wang IJ. Quality of vision after laser in situ keratomileusis: influence of diopteric correction and pupil size on visual function. J Cataract Refract Surg 2003; 29: 769–77PubMedCrossRef

105.

Gartry DS, Kerr Muir MG, Marshall J. The effect of topical corticosteroids on refraction and corneal haze following excimer laser treatment of myopia: an update. A prospective, randomised, double-masked study. Eye 1993; 7: 584–90

106.

O’Brart DP, Lohmann CP, Klonos G, et al. The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy: a prospective, randomized, observer-masked study. Ophthalmology 1994; 101(9): 1565–74PubMed

107.

Arshinoff S, D’Addario D, Sadler C, et al. Use of topical nonsteroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy. J Cataract Refract Surg 1994; Suppl.: 216–22

108.

Talamo GH, Gollamudi S, Green WR, et al. Modulation of corneal wound healing after excimer laser keratomileusis using topical mitomycin C and steroids. Arch Ophthalmol 1991; 109: 1141–6PubMedCrossRef

109.

Schipper I, Suppelt C, Gebbers JO. Mitomycin C reduces scar formation after excimer laser (193 nm) photorefractive keratectomy in rabbits. Eye 1997; 11: 649–55PubMedCrossRef

110.

Xu H, Liu S, Xia X, et al. Mitomycin C reduces haze formation in rabbits after excimer laser photorefractive keratectomy. J Refract Surg 2001; 17(3): 342–9PubMed

111.

Majmudar PA, Forstet SL, Dennis RF, et al. Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology 2000; 107(1): 89–94PubMedCrossRef

112.

Carones F, Vigo L, Scandola E, et al. Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. J Cataract Refract Surg 2002; 28(12): 2088–95PubMedCrossRef

113.

Gambato C, Ghirlando A, Moretto E, et al. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology 2005; 112(2): 208–18PubMedCrossRef

114.

Chalita MR, Roth AS, Krueger RR. Wavefront-guided surface ablation with prophylactic use of mitomycin C after a button-hole laser in situ keratomileusis flap. J Refract Surg 2004; 20(2): 176–81PubMed

115.

Muller LT, Candal EM, Epstein RJ, et al. Transepithelial phototherapeutic keratectomy/photorefractive keratectomy with adjunctive mitomycin-C for complicated LASIK flaps. J Cataract Refract Surg 2005; 31(2): 291–6PubMedCrossRef

116.

Eschele-Meniconi ME, Ahmad SR, Foster CS. Mucous membrane pemphigoid: an update. Curr Opin Ophthalmol 2005; 16(5): 303–7CrossRef

117.

Donnenfeld ED, Perry HD, Wallerstein A, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology 1999; 106(1): 72–8PubMedCrossRef

118.

Celis Sanchez J, Lopez Ferrando N, Garcia Largacha M, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Arch Soc Esp Oftalmol 2002; 77(9): 501–6PubMed

119.

Solomon A, Espana EM, Tseng SC. Amniotic membrane transplantation for reconstruction of the conjunctival fornices. Ophthalmology 2003; 110: 93–100PubMedCrossRef

120.

Secchi AG, Tognon MS. Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices. Am J Ophthalmol 1996; 122(5): 728–30PubMed

121.

Tseng SC, Di Pascuale MA, Liu DT, et al. Intraoperative mitomycin C and amniotic membrane transplantation for fornix reconstruction in severe cicatricial ocular surface diseases. Ophthalmology 2005; 112(5): 896–903PubMedCrossRef

122.

Majumdar PA, Epstein RJ. Antimetabolites in ocular surface neoplasia. Curr Opin Ophthalmol 1998; 9: 35–9CrossRef

123.

Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors: the 1994 Lynn B McMahan Lecture. Arch Ophthalmol 1997; 115(6): 808–15PubMedCrossRef

124.

Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol 1995; 39(6): 429–50PubMedCrossRef

125.

Frucht-Pery J, Rozenman Y. Mitomycin C therapy for corneal intraepithelial neoplasia. Am J Ophthalmol 1994; 117(2): 164–8PubMed

126.

Wilson MW, Hungerford JL, George SM, et al. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol 1997; 124(3): 303–11PubMed

127.

Heigle TJ, Stalling RD, Palay DA. Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C. Am J Ophthalmol 1997; 124(3): 397–9PubMed

128.

Frucht-Pery J, Sugar J, Baum J, et al. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. Ophthalmology 1997; 104(12): 2085–93PubMed

129.

Rozenman Y, Frucht-Pery J. Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C. Cornea 2000; 19(1): 1–6PubMedCrossRef

130.

Akpek EK, Ertoy D, Kalayci D, et al. Postoperative topical mitomycin C in conjunctival squamous cell neoplasia. Cornea 1999; 18(1): 59–62PubMedCrossRef

131.

Siganos CS, Kozobolis VP, Christodoulakis EV. The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea 2002; 21(1): 12–6PubMedCrossRef

132.

Yamamoto N, Ohmura T, Suzuki H, et al. Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C. Ophthalmology 2002; 109(2): 249–52PubMedCrossRef

133.

Di Pascuale MA, Espana EM, Tseng SC. A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles. Cornea 2004; 23(1): 89–92PubMedCrossRef

134.

Kemp EG, Harnett AN, Chatterjee S. Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol 2002; 86(1): 31–4PubMedCrossRef

135.

Chen C, Louis D, Dodd T, et al. Mitomycin C as an adjunct in the treatment of localized ocular surface squamous neoplasia. Br J Ophthalmol 2004; 88(1): 17–8PubMedCrossRef

136.

Prabhasawat P, Tarinvorakup P, Tesavibul N, et al. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea 2005; 24(4): 443–8PubMedCrossRef

137.

Corcoran KT, Marsich MM, Ward DC. Potentially life threatening primary acquired melanosis. Clin Eye Vis Care 2000; 12: 185–8PubMedCrossRef

138.

Folberg R, McLean IW, Zimmerman LE. Conjunctival melanosis and melanoma. Ophthalmology 1984; 91: 673–8PubMed

139.

Norregaard JC, Gerner N, Jensen OA, et al. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol 1996; 234: 569–72PubMedCrossRef

140.

Frucht-Pery J, Pe’er J. Use of mitomycin C in the treatment for conjunctival primary acquired melanosis with atypia. Arch Ophthalmol 1996; 114: 1261–4PubMedCrossRef

141.

Pe’er J, Frucht-Pery J. The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C. Am J Ophthalmol 2005; 139(2): 229–34PubMedCrossRef

142.

Seregard S. Conjunctival Melanoma. Surv Ophthalmol 1998; 42: 321–50PubMedCrossRef

143.

Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas. Ophthal Plastic Reconstr Surg 1998; 14: 208–15CrossRef

144.

Jakobiec FA, Brownstein S, Wilkinson RD, et al. Combined surgery and cryotherapy for diffuse malignant melanoma of the conjunctiva. Arch Ophthalmol 1980; 98: 1390–6PubMedCrossRef

145.

Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol 2002; 25(3): 248–55PubMedCrossRef

146.

Wilson MW, Schelonka LP, Siegel D, et al. Immunohistochemical localization of NAD(P)H:quinone oxidoreductase in conjunctival melanomas and primary acquired melanosis. Curr Eye Res 2001; 22(5): 348–52PubMedCrossRef

147.

Demirci H, McCormick SA, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol 2000; 118(7): 885–91PubMed

148.

Greenfield DS, Leibmann JM, Suner IJ, et al. Late onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol 1998; 116: 443–7PubMed

149.

Greenfield DS, Suner IJ, Miller MP. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996; 114(8): 943–9PubMedCrossRef

150.

Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea 1996; 15(5): 537–40PubMedCrossRef

151.

Smith S, D’Amore PA, Dreyer FB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. Am J Ophthalmol 1994 15; 118(3): 332–7PubMed

152.

Scott IU, Cruz-Villegas V, Flynn HW, et al. Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. Am J Ophthalmol 2004; 137(3): 583–5PubMedCrossRef

153.

Song A, Scott IU, Flynn HW, et al. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology 2002; 109(5): 985–91PubMedCrossRef

154.

Hsiao CH, Chen JJ, Huang SC, et al. Intrascleral dissemination of infectious scleritis following pterygium excision. Br J Ophthalmol 1998; 82(1): 29–34PubMedCrossRef

155.

Singh RP, McCulskey P. Scedosporium prolificans sclerokeratitis 10 years after pterygium excision with adjunctive mitomycin C. Clin Experiment Ophthalmol 2005; 33(4): 433–4PubMedCrossRef

156.

Dudney BW, Malecha MA. Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. Am J Ophthalmol 2004; 137(5): 950–1PubMedCrossRef

157.

Billing K, Karagiannis A, Selva D. Punctal-canalicular stenosis associated with mitomycin-C for corneal epithelial dysplasia. Am J Ophthalmol 2003; 136(4): 746–7PubMedCrossRef

158.

Salomao DR, Mathers WD, Sutphin JE, et al. Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. Ophthalmology 1999; 106(9): 1756–60PubMedCrossRef

159.

Sacu S, Segur-Eltz N, Horvat R, et al. Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma. Am J Ophthalmol 2003; 136(2): 375–7PubMedCrossRef

160.

Cruz OA, Matkovich L. Effects of intraoperative topical mitomycin-C on strabismus surgery in the rabbit: a preliminary study. Ophthalmic Surg 1995; 26(3): 237–40PubMed

161.

Mahindrakar A, Tandon R, Menon V, et al. Effectiveness of mitomycin C in reducing reformation of adhesions following surgery for restrictive strabismus. J Pediatr Ophthalmol Strabismus 2001; 3(3): 131–5

162.

Edelstein C, Shields CL, De Potter P, et al. Complications of motility peg placement for the hydroxyapatite orbital implant. Ophthalmology 1997; 104(10): 1616–21PubMed

163.

Lew H, Lee SY, Yang WI, et al. A morphological study of drill holes applied with mitomycin-C in hydroxyapatite orbital implants. Ophthal Res 2001; 33(6): 340–4CrossRef

164.

Wu WC, Kao YH, Hu DN. A comparative study of effects of antiproliferative drugs on human retinal pigment epithelial cells in vitro. J Ocul Pharmacol Ther 2002; 18(3): 251–64PubMedCrossRef

165.

Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1993; 11: 632–5CrossRef

166.

Spoor TC, McHenry JG, Shin DH. Long-term results using adjunctive mitomycin C in optic nerve sheath decompression for pseudotumor cerebri. Ophthalmology 1995; 102: 2024–8PubMed

167.

Mietz H, Prager TC, Schweitzer C, et al. Effect of mitomycin C on the optic nerve in rabbits. Br J Ophthalmol 1997; 81(7): 584–859PubMedCrossRef

168.

Haus CM, Galand AL. Mitomycin against posterior capsular opacification: an experimental study in rabbits. Br J Ophthalmol 1996; 80(12): 1087–91PubMedCrossRef

169.

Shin DH, Kim YY, Ren J, et al. Decrease of capsular opacification with adjunctive mitomycin C in combined glaucoma and cataract surgery. Ophthalmology 1998; 105(7): 1222–6PubMedCrossRef

170.

Akpek EK, Hasiripi H, Christen WG, et al. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology 2000; 107(2): 263–9PubMedCrossRef

171.

Sodhi PK, Pandey RM, Ratan SK. Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis. Cornea 2003; 22(3): 210–3PubMedCrossRef

172.

Tanaka M, Takano Y, Dogru M, et al. A comparative evaluation of the efficacy of intraoperative mitomycin C use after the excision of cobblestone-like papillae in severe atopic and vernal keratoconjunctivitis. Cornea 2004; 23(4): 326–9PubMedCrossRef

Titel: Mitomycin
Clinical Applications in Ophthalmic Practice
verfasst von: Lekha M. Abraham
Dinesh Selva
Robert Casson
Dr Igal Leibovitch
Publikationsdatum: 01.02.2006
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 3/2006
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200666030-00005

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2006

Mammalian Cell-Derived Somatropin

Letrozole in Postmenopausal Hormone-Responsive Early-Stage Breast Cancer

Letrozole

Remifentanil

Should Postprandial Hyperglycaemia in Prediabetic and Type 2 Diabetic Patients be Treated?

Travellers’ Diarrhoea: Contemporary Approaches to Therapy and Prevention